Table 2.
Meta-analytical evidence for biomarker specificity of regional atrophy in CBS/CBD as measured with MRI
| Disease | Study | Anatomical region | ||||
|---|---|---|---|---|---|---|
| Thalamus | Bl. fronto-median and midcingulate cortex | Bl. premotor area and supplementary motor area | L. pre-central gyrus | L. superior frontal sulcus and middle frontal gyrus | ||
| Parkinson’s syndromes | ||||||
| Parkinson’s disease | 15, 16 | − | − | − | + | + |
| Atypical Parkinson’s syndromes | ||||||
| CBD and syndrome | Present meta-analysis | + | + (posterior) | + | + | + |
| Progressive supranuclear palsy | 15 | + | − | − | + | − |
| Multiple system atrophy | 16 | + | − | − | − | − |
| Lewy body dementia | 40* | (−) | (−) | (−) | (−) | (−) |
| Alzheimer’s disease | 9, 12, 41 | + | − | − | − | − |
| Behavioral variant frontotemporal dementia | 8–11 | − | + (anterior) | − | − | − |
| Primary progressive aphasias | ||||||
| Nonfluent/ agrammatic variant (progressive non-fluent aphasia) | 9, 10, 42 | − | − | − | − | + |
| Semantic variant (semantic dementia) | 9, 10, 42, 43 | − | − | − | − | − |
| Logopenic variant (logopenic aphasia) | 42 | − | − | − | − | − |
Meta-analyses were conducted by calculating ALEs in the gray matter. Other methods, such as effect-size signed differential mapping, were not taken into account to avoid a bias of different methods.
*Only one study by Zhong et al.40 applying anisotropic effect size version of signed differential mapping (AES-SDM) was included, because no ALE meta-analysis has been available to date.
Bl bilateral, L left, NR not reported to date